{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:28:45Z","timestamp":1783715325337,"version":"3.55.0"},"reference-count":115,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2019,10,2]]},"DOI":"10.1080\/14728214.2019.1685494","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T14:38:13Z","timestamp":1572273493000},"page":"221-231","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":29,"title":["Emerging antibiotics for community-acquired pneumonia"],"prefix":"10.1080","volume":"24","author":[{"given":"Adamantia","family":"Liapikou","sequence":"first","affiliation":[{"name":"6st Respiratory Department, Sotiria Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Cilloniz","sequence":"additional","affiliation":[{"name":"Respiratory Institute, CIBERES- IDIBAPS C, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palomeque","sequence":"additional","affiliation":[{"name":"Respiratory Institute, CIBERES- IDIBAPS C, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Torres","sequence":"additional","affiliation":[{"name":"Respiratory Institute, CIBERES- IDIBAPS C, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.02.007"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000466"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0140OC"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.09.041"},{"key":"e_1_3_3_7_1","first-page":"6(20)","article-title":"Characteristics and management of community-acquired pneumonia in the era of global aging","author":"Cill\u00f3niz C","year":"2018","unstructured":"Cill\u00f3niz C, Rodr\u00edguez-Hurtado D, Torres A. Characteristics and management of community-acquired pneumonia in the era of global aging. Med Sci (Basel). 2018;6(20).","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2371-3"},{"key":"e_1_3_3_9_1","first-page":"7(2)","article-title":"PES pathogens in severe community-acquired pneumonia","author":"Cill\u00f3niz C","year":"2019","unstructured":"Cill\u00f3niz C, Domined\u00f2 C, Nicolini A, et al. PES pathogens in severe community-acquired pneumonia. Microorganisms. 2019;7(2).","journal-title":"Microorganisms"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203384"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.09.023"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.04.006"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.143982"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.10.020"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200504"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy263"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201407-305OC"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01190-2017","article-title":"GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients","volume":"52","author":"Restrepo MI","year":"2018","unstructured":"Restrepo MI, Babu BL, Reyes LF, et al. GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52(2).","journal-title":"Eur Respir J"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.042"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2013.01.006"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw300"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis022"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2018.38.3.266"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01630.x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy044"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.143"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-307"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2012.06.001"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000788"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00676-11"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz152"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12363"},{"key":"e_1_3_3_34_1","first-page":"713e717","article-title":"Antibiotic innovation for future public health needs","volume":"23","author":"Theuretzbacher U","year":"2017","unstructured":"Theuretzbacher U. Antibiotic innovation for future public health needs. Rev Clin Microbiol Infect. 2017;23:713e717.","journal-title":"Rev Clin Microbiol Infect"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.09.025"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-12-22"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20160077"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0036-8"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0023-0"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks069"},{"issue":"3","key":"e_1_3_3_42_1","first-page":"iii19","article-title":"FOCUS 1: a randomized, double blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File TM","year":"2011","unstructured":"File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl3):iii19\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr097"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03643-14"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3791-z"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.01.014"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw062"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-013-0010-x"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020063"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.010"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_3_52_1","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","author":"Shoen C","year":"2019","unstructured":"Shoen C, Benaroch D, Sklaney M, et al. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;AAC:02522\u201302518.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_3_55_1","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT02531438?term=NCT02531438&draw=2&rank=1"},{"key":"#cr-split#-e_1_3_3_56_1.1","unstructured":"Paratek announces positive Phase 3 study of Omadacycline in community-acquired bacterial pneumonia. [updated 2017 Apr 3"},{"key":"#cr-split#-e_1_3_3_56_1.2","unstructured":"cited 2017 May 16]. Available from www.globenewswire.com"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_58_1","doi-asserted-by":"crossref","unstructured":"Omadacycline (Nuzyra) - A new tetracycline antibiotic. JAMA. 2019;322(5):457\u2013458. Available from: https:\/\/www.drugs.com\/history\/nuzyra.html","DOI":"10.1001\/jama.2019.8199"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-10"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0667-z"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01123-09"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04652-14"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-12"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00197-13"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00017-7"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw490"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.08.035"},{"key":"e_1_3_3_68_1","unstructured":"FDA briefing document solithromycin oral capsule and injection meeting of the antimicrobial drugs advisory committee (AMDAC). cited 2016 Nov 4. Available from https:\/\/www.fda.gov"},{"key":"e_1_3_3_69_1","unstructured":"Available from: https:\/\/www.fdanews.com\/articles\/180038-fda-declines-to-approve-cempras-cabp-antibiotic-solithera?v=preview"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.09.001"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S63581"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.2165\/11632780-000000000-00000"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp144"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2015.09.005"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00295-10"},{"key":"e_1_3_3_76_1","unstructured":"Cheng S Wu R Hsu Z et al. Efficacy and Safety of Oral Nemonoxacin in Treatment of Community-Acquired Pneumonia: subgroup Analysis Results in Taiwanese Patients in a Randomized Double-Blind Multi-Center Phase III Comparative Study with Levofloxacin. 2015;191:A4063. Available from: www.atsjournals.org\/doi\/abs\/10.1164\/ajrccmconference.2015.191.1_MeetingAbstracts.A4063."},{"key":"e_1_3_3_77_1","unstructured":"TaiGen Biotechnology. A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP. 2016. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02205112?term=NCT02205112&draw=2&rank=1"},{"key":"e_1_3_3_78_1","doi-asserted-by":"crossref","unstructured":"Poole RM. Nemonoxacin: first global approval. Drugs. 2014;74:1445\u20131453. Available from: https:\/\/adisinsight.springer.com\/drugs\/800022726","DOI":"10.1007\/s40265-014-0270-0"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl304"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0150-4"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S90948"},{"key":"e_1_3_3_82_1","first-page":"A1","volume-title":"Program and abstract of 50th Interscience conference on antimicrobial agents and chemotherapy","author":"Marra A","year":"2011","unstructured":"Marra A, Bortolon E, Molstad D, et al. Evaluation of delafloxacin in rat granuloma pouch infections caused by gram- negative pathogens. In: Program and abstract of 50th Interscience conference on antimicrobial agents and chemotherapy. Chicago, USA: Abstract; 2011. p. A1\u2013680."},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02609-16"},{"key":"e_1_3_3_86_1","unstructured":"Sheikh J Clinical microbiology review. Delafloxacin. NDA#208610 208611. Melinta Therapeutics Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-13"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.08.012"},{"key":"e_1_3_3_89_1","unstructured":"Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02679573?term=NCT02679573&draw=2&rank=1"},{"key":"e_1_3_3_90_1","unstructured":"A comparative evaluation of the single dose efficacy of oral delafloxacin versus the single-dose efficacy of an intramuscular injection of ceftriaxone in subjects with uncomplicated urogenital gonorrhea. Identifier NCT02015637. cited 2014 Nov 12. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02015637?term=NCT02015637&rank=1"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1079"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06219.x"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv442"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-18"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02106-12"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01497-17"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090"},{"key":"e_1_3_3_101_1","unstructured":"Seltzer E Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia (LEAP). 2016. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02559310?term=lefamulin&draw=2&rank=3"},{"key":"e_1_3_3_102_1","unstructured":"Gasink L Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia (LEAP2). 2016. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02813694?term=lefamulin&draw=2&rank=2"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep39004"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003725"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001342"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5007275"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3212"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy547"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01497-15"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401184"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-15"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5017768"}],"updated-by":[{"DOI":"10.1080\/14728214.2019.1710062","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000}}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2019.1685494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:14:45Z","timestamp":1770912885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2019.1685494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10,2]]}},"alternative-id":["10.1080\/14728214.2019.1685494"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2019.1685494","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}